Bispecific anti-VEGF and anti-TrkB binding molecules for the treatment of eye diseases

US12110335B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Peter Michael Benz · Veitshöchheim, DE
• Remko Alexander BAKKER · Biberach an der Riß, DE
• Holger Fuchs · Aalen, DE
• Fei HAN · Sandy Hook, US
• Sandeep Kumar · Sunnyvale, US
• Sarah Low · Carmel, US
• Justin Scheer · San Francisco, US
• Leo Thomas · Biberach, DE

Key dates

• Filing date: Oct 20, 2021
• Grant date: Oct 8, 2024
• Expiry date: Oct 20, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to binding molecules that bind specifically Vascular Endothelial Growth Factor (VEGF) and Tropomyosin receptor kinase B (TrkB) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of diseases of the eye.